Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$24.71 USD
-0.29 (-1.16%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $24.72 +0.01 (0.04%) 5:12 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.71 USD
-0.29 (-1.16%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $24.72 +0.01 (0.04%) 5:12 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Zacks News
Dentsply International (XRAY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.
Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.
CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1
by Zacks Equity Research
CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.
LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised
by Zacks Equity Research
LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.
Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.
OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.
Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.
Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.
Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.
Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.
Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up
by Zacks Equity Research
Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.
Stryker (SYK) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.
InMode (INMD) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.
Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong
by Zacks Equity Research
The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.
Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid
by Zacks Equity Research
Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako and broad product portfolio. However, pricing pressure raises a concern.
Veeva Systems (VEEV) Inks Deal to Advance Clinical Trials
by Zacks Equity Research
Veeva Systems (VEEV) collaborates with Parexel to accelerate clinical trials by combining the best of each company's experience.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.
MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth
by Urmimala Biswas
While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.